1027550-08-8

Basic information

• Product Name: 2-chloro-5-[2-(8-oxo-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-ethyl]-benzoic acid methyl ester
• CAS NO: 1027550-08-8
• Molecular Weight: 346.773
• Mol File: 1027550-08-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-chloro-5-[2-(8-oxo-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-ethyl]-benzoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-5-[2-(8-oxo-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-ethyl]-benzoic acid methyl ester(1027550-08-8)
• EPA Substance Registry System: 2-chloro-5-[2-(8-oxo-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-ethyl]-benzoic acid methyl ester(1027550-08-8)

Safety Data

• Hazardous Substances Data: 1027550-08-8(Hazardous Substances Data)

Upstream product

• 72079-77-7 6,7-dihydroimidazo<4,5-d><1,3>diazepin-8(3H)-one 
• 272130-89-9 5-(2-bromo-ethyl)-2-chloro-benzoic acid methyl ester 
• 272130-86-6 methyl 2-chloro-5-(2-hydroxyethyl)benzoate 
• 272130-85-5 methyl 2-chloro-5-ethenylbenzoate 
• 251085-87-7 methyl 5-bromo-2-chloro-benzoate 

Downstream Products

• 1027229-46-4 2-chloro-5-[2-(8-hydroxy-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-ethyl]-benzoic acid methyl ester 

Relevant articles and documents

AMP deaminase inhibitors. 3. SAR of 3-(carboxyarylalkyl)coformycin aglycon analogues

N3-Substituted coformycin aglycon analogues with improved AMP deaminase (AMPDA) inhibitory potency are described. Replacement of the 5-carboxypentyl substituent in the lead AMPDA inhibitor 3-(5-carboxypentyl)-3,6,7,8- tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol (2) described in the previous article with various carboxyarylalkyl groups resulted in compounds with 10- 100-fold improved AMPDA inhibitory potencies. The optimal N3 substituent had m-carboxyphenyl with a two-carbon alkyl tether. For example, 3-[2-(3-carboxy- 5-ethylphenyl)ethyl]-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol (43g) inhibited human AMPDA with a K(i) = 0.06 μM. The compounds within the series also exhibited > 1000-fold specificity for AMPDA relative to adenosine deaminase.